Article | November 20, 2017

What's Behind The Industry's Persistent Study Build Delays?

Source: Medrio
What’s Behind The Industry’s Persistent Study Build Delays?

The Tufts Center for the Study of Drug Development, in conjunction with Veeva Systems, released its 2017 eClinical Landscape Study in October, and among the results is a troubling statistic: Companies conducting clinical trials are taking an average of 68 days to build their studies, with 77% of survey respondents reporting problems entering data into their electronic data capture (EDC) solution.

This comes at a time when EDC has grown into a robust industry, with a whole host of companies working to create innovations that have unlocked capabilities that early developers of the technology never imagined. These innovations are purported to make EDC more flexible and efficient, and to accelerate data management as a result. So why is the average study build timeline still hovering at over two months?